CalciMedica, Inc.
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
CALC | NDAQ
Overview
Corporate Details
- ISIN(s):
- US38942Q2021 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 505 COAST BOULEVARD SOUTH, 92037 LA JOLLA
- Website:
- https://calcimedica.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for life-threatening acute inflammatory and immunologic diseases. The company specializes in a new class of treatments based on the inhibition of calcium release-activated calcium (CRAC) channels, which are designed to modulate the immune response and protect against tissue cell injury. Its lead product candidate, Auxora™ (zegocractin), is a proprietary small molecule CRAC channel inhibitor being developed for critical care illnesses with high unmet needs, including acute kidney injury (AKI) and acute pancreatitis (AP), for which there are currently no approved disease-modifying treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CalciMedica, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CalciMedica, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CalciMedica, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
